Dr. Seillier is a neuroscientist, with expertise in pre-clinical neuropsychopharmacology and in-depth insight into multiple behavioral paradigms and animal models. His overarching research theme centers on understanding the neuropsychopharmacology underpinnings of the negative symptoms of schizophrenia. He is the head of the Schizophrenia Models for Advancing Research and Treatment workgroup.

Dr. Seillier received his B.Sc. in Biology (Cellular Biology and Physiology) from Henry Poincaré University (Nancy, France) and his M.Sc. in Neurosciences (Behavioral and Cognitive Neurosciences) from Louis Pasteur University (Strasbourg, France). He then obtained a doctoral fellowship allocated by the French Ministry of National Education, Research and Technology to continue his research training in Strasbourg, where he completed his Ph.D. in Neurosciences in 2004.

As a postdoctoral fellow, he has been instrumental in establishing schizophrenia research in the laboratory of Prof. Giuffrida. (San Antonio, Texas). As an outgrowth of this task, he was actively involved in redefining the “cannabinoid hypothesis of schizophrenia”, and received several awards by the Society of Neuroscience in recognition of the scientific relevance of this work. Given his achievements, Dr. Seillier was promoted to a research-track faculty position in 2010. As an Instructor in the Department of Pharmacology at the University of Texas Health Science Center at San Antonio, he focused his research on the role played by the endocannabinoid system in schizophrenia, with a special emphasis on the negative symptomatology of this disease.

Before joining the National Institute of Mental Health, Dr. Seillier was a micro-entrepreneur and served as an independent consultant (after moving back to Europe). He is also the founder of CogitActive.